The US pharmaceutical major Panacea will open a state-of-the-art Cancer Research Centre at Qatar Science and Technology Park (QSTP). The QSTP Center will be Panacea’s first and exclusive research institute for the MENA region, Professor Dr Hossein Ghanbari (pictured) , Chairman and CEO of Pancea Pharmaceuticals told The Peninsula yesterday.
Dr Ghanbari said Panacea-MENA will have three divisions including Cancer Testing Laboratories, Proteus Imaging and Cancer Vaccine Therapy Clinics. The screening tests will cover high risk prostrate, bladder and lung cancer patients. The surveillance tests will cover individuals susceptible to liver cancer, breast cancer, colorectal cancer, pancreatic cancer and Bile duct cancer.
The Panacea’s Lung Cancer Test (LC Detect TM) was chosen among Time magazine’s Top 10 medical breakthroughs of 2007. Panacea was also in the headlines for developing critical tests for prostrate cancer (PC Detect), breast cancer (BC Detect SM), lung cancer (LC Detect) and colorectal cancer (CC Detect SM). Colorectal cancer is the most common cancer detected overall in the US. Screening and surveillance tests are often invasive and expensive. An effective non-invasive screening test would lead to earlier diagnosis in some people, better compliance and increased cost-effectiveness. A simple, non-invasive surveillance test would likewise result in better compliance and earlier detection of recurrence.
In the US, the target of CC DetectSM is over 60m people. People at high or increased risk include those with a history of colorectal adenoma, ovarian or breast cancer, people with previous colorectal cancer, people with inflammatory bowel disease, people with high fat diets; obesity, cigarette smokers and heavy
Follow us on our social media channels: